Phase 2 × Hemangiosarcoma × Dermatologic × Clear all
NCT02834013 2026-03-18

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
818 enrolled
NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Novartis

Phase 2 Completed
185 enrolled
NCT00526149 2013-10-07

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
76 enrolled